請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28219
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 沈麗娟 | |
dc.contributor.author | Ying-Luen Chen | en |
dc.contributor.author | 陳瑩倫 | zh_TW |
dc.date.accessioned | 2021-06-13T00:02:58Z | - |
dc.date.available | 2016-07-31 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-05 | |
dc.identifier.citation | 參考文獻
1. Stolnik, S. & Shakesheff, K. Formulations for delivery of therapeutic proteins. Biotechnol Lett 31, 1-11 (2009). 2. Stewart, K.M., Horton, K.L. & Kelley, S.O. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 6, 2242-2255 (2008). 3. Patel, L.N., Zaro, J.L. & Shen, W.C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 24, 1977-1992 (2007). 4. Zorko, M. & Langel, U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 57, 529-545 (2005). 5. Vives, E., Schmidt, J. & Pelegrin, A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786, 126-138 (2008). 6. Fernandez-Carneado, J., Kogan, M.J., Pujals, S. & Giralt, E. Amphipathic peptides and drug delivery. Biopolymers 76, 196-203 (2004). 7. Murriel, C.L. & Dowdy, S.F. Influence of protein transduction domains on intracellular delivery of macromolecules. Expert Opin Drug Deliv 3, 739-746 (2006). 8. Trehin, R., Krauss, U., Beck-Sickinger, A.G., Merkle, H.P. & Nielsen, H.M. Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat(47-57) through well-differentiated epithelial models. Pharm Res 21, 1248-1256 (2004). 9. Foerg, C., Ziegler, U., Fernandez-Carneado, J., Giralt, E. & Merkle, H.P. Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells corresponds with activities of Rho-GTPases. Pharm Res 24, 628-642 (2007). 10. Koppelhus, U., et al. Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev 12, 51-63 (2002). 11. Vives, E., Brodin, P. & Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272, 16010-16017 (1997). 12. Fernandez-Carneado, J., Kogan, M.J., Castel, S. & Giralt, E. Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of gamma-zein. Angew Chem Int Ed Engl 43, 1811-1814 (2004). 13. Nath, A., et al. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 70, 1475-1480 (1996). 14. Zaro, J.L. & Shen, W.C. Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem Biophys Res Commun 307, 241-247 (2003). 15. Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R. & Brock, R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 848-866 (2007). 16. Mueller, J., Kretzschmar, I., Volkmer, R. & Boisguerin, P. Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjug Chem 19, 2363-2374 (2008). 17. Lundin, P., et al. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug Chem 19, 2535-2542 (2008). 18. Szeto, H.H., Schiller, P.W., Zhao, K. & Luo, G. Fluorescent dyes alter intracellular targeting and function of cell-penetrating tetrapeptides. FASEB J 19, 118-120 (2005). 19. Thoren, P.E., et al. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells. Biochem Biophys Res Commun 307, 100-107 (2003). 20. Conner, S.D. & Schmid, S.L. Regulated portals of entry into the cell. Nature 422, 37-44 (2003). 21. Zaro, J.L. & Shen, W.C. Evidence that membrane transduction of oligoarginine does not require vesicle formation. Exp Cell Res 307, 164-173 (2005). 22. Zaro, J.L. & Shen, W.C. Cytosolic delivery of a p16-peptide oligoarginine conjugate for inhibiting proliferation of MCF7 cells. J Control Release 108, 409-417 (2005). 23. Fittipaldi, A., et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 278, 34141-34149 (2003). 24. Pujals, S., Fernandez-Carneado, J., Lopez-Iglesias, C., Kogan, M.J. & Giralt, E. Mechanistic aspects of CPP-mediated intracellular drug delivery: relevance of CPP self-assembly. Biochim Biophys Acta 1758, 264-279 (2006). 25. Pethe, K., et al. The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412, 190-194 (2001). 26. Locht, C., Hougardy, J.M., Rouanet, C., Place, S. & Mascart, F. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb) 86, 303-309 (2006). 27. Delogu, G. & Brennan, M.J. Functional domains present in the mycobacterial hemagglutinin, HBHA. J Bacteriol 181, 7464-7469 (1999). 28. Menozzi, F.D., et al. Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med 184, 993-1001 (1996). 29. Menozzi, F.D., et al. Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions. Microbes Infect 8, 1-9 (2006). 30. Masungi, C., et al. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis 185, 513-520 (2002). 31. Parra, M., et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 72, 6799-6805 (2004). 32. 鄭如辰. 研究肝素結合凝血附著素相關胜肽之穿胞運輸性質. National Taiwan University (2009). 33. Chorev, M. & Goodman, M. Recent developments in retro peptides and proteins--an ongoing topochemical exploration. Trends Biotechnol 13, 438-445 (1995). 34. Chorev, M. The partial retro-inverso modification: a road traveled together. Biopolymers 80, 67-84 (2005). 35. Trehin, R., et al. Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat(47-57) and penetratin(43-58). Biochem J 382, 945-956 (2004). 36. Wender, P.A., et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 97, 13003-13008 (2000). 37. Elmquist, A. & Langel, U. In vitro uptake and stability study of pVEC and its all-D analog. Biol Chem 384, 387-393 (2003). 38. Takaku, H., Matsumoto, M., Misawa, S. & Miyazaki, K. Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism. Jpn J Cancer Res 86, 840-846 (1995). 39. Ormerod, M.G., Orr, R.M. & Peacock, J.H. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br J Cancer 69, 93-100 (1994). 40. Gong, H., Zolzer, F., von Recklinghausen, G., Havers, W. & Schweigerer, L. Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 14, 826-829 (2000). 41. Shen, L.J., Beloussow, K. & Shen, W.C. Modulation of arginine metabolic pathways as the potential anti-tumor mechanism of recombinant arginine deiminase. Cancer Lett 231, 30-35 (2006). 42. Izzo, F., et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22, 1815-1822 (2004). 43. Ascierto, P.A., et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23, 7660-7668 (2005). 44. Ensor, C.M., Holtsberg, F.W., Bomalaski, J.S. & Clark, M.A. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62, 5443-5450 (2002). 45. Shen, L.J., Lin, W.C., Beloussow, K. & Shen, W.C. Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 191, 165-170 (2003). 46. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63 (1983). 47. Morgan, D.M. Tetrazolium (MTT) assay for cellular viability and activity. Methods Mol Biol 79, 179-183 (1998). 48. Beloussow, K., Wang, L., Wu, J., Ann, D. & Shen, W.C. Recombinant arginine deiminase as a potential anti-angiogenic agent. Cancer Lett 183, 155-162 (2002). 49. Yu, H.H., Wu, F.L., Lin, S.E. & Shen, L.J. Recombinant arginine deiminase reduces inducible nitric oxide synthase iNOS-mediated neurotoxicity in a coculture of neurons and microglia. J Neurosci Res 86, 2963-2972 (2008). 50. Chaloin, L., De, E., Charnet, P., Molle, G. & Heitz, F. Ionic channels formed by a primary amphipathic peptide containing a signal peptide and a nuclear localization sequence. Biochim Biophys Acta 1375, 52-60 (1998). 51. Oehlke, J., et al. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta 1414, 127-139 (1998). 52. Hallbrink, M., et al. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 1515, 101-109 (2001). 53. Lindgren, M.E., Hallbrink, M.M., Elmquist, A.M. & Langel, U. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem J 377, 69-76 (2004). 54. Holm, T., et al. Retro-inversion of certain cell-penetrating peptides causes severe cellular toxicity. Biochim Biophys Acta 1808, 1544-1551 (2011). 55. Futaki, S., et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276, 5836-5840 (2001). 56. Suzuki, T., et al. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 277, 2437-2443 (2002). 57. Pujals, S., Fernandez Carneado, J., Ludevid, M.D. & Giralt, E. D SAP: A New, Noncytotoxic, and Fully Protease Resistant Cell Penetrating Peptide. ChemMedChem 3, 296-301 (2008). 58. Boderke, P., Merkle, H.P., Cullander, C., Ponec, M. & Bodde, H.E. Localization of aminopeptidase activity in freshly excised human skin: direct visualization by confocal laser scanning microscopy. J Invest Dermatol 108, 83-86 (1997). 59. Rennert, R., Wespe, C., Beck-Sickinger, A.G. & Neundorf, I. Developing novel hCT derived cell-penetrating peptides with improved metabolic stability. Biochim Biophys Acta 1758, 347-354 (2006). 60. Wang, H., Yi, T., Zheng, Y. & He, S. Induction of monocyte chemoattractant protein-1 release from A549 cells by agonists of protease-activated receptor-1 and -2. Eur J Cell Biol 86, 233-242 (2007). 61. Fix, J.A. Oral controlled release technology for peptides: status and future prospects. Pharm Res 13, 1760-1764 (1996). 62. Garner, P., Sherry, B., Moilanen, S. & Huang, Y. In vitro stability of alpha-helical peptide nucleic acids (alphaPNAs). Bioorg Med Chem Lett 11, 2315-2317 (2001). 63. Hong, S.Y., Oh, J.E. & Lee, K.H. Effect of D-amino acid substitution on the stability, the secondary structure, and the activity of membrane-active peptide. Biochem Pharmacol 58, 1775-1780 (1999). 64. Hamamoto, K., Kida, Y., Zhang, Y., Shimizu, T. & Kuwano, K. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol 46, 741-749 (2002). 65. Li, C., et al. Limitations of peptide retro-inverso isomerization in molecular mimicry. J Biol Chem 285, 19572-19581 (2010). 66. Huang, Y. & Hui, D.Y. Metabolic fate of pancreas-derived cholesterol esterase in intestine: an in vitro study using Caco-2 cells. J Lipid Res 31, 2029-2037 (1990). 67. Jones, S.W., et al. Characterisation of cell-penetrating peptide-mediated peptide delivery. Br J Pharmacol 145, 1093-1102 (2005). 68. Rusnati, M., et al. Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. J Biol Chem 274, 28198-28205 (1999). 69. Ziegler, A. & Seelig, J. Binding and clustering of glycosaminoglycans: a common property of mono- and multivalent cell-penetrating compounds. Biophys J 94, 2142-2149 (2008). 70. David, G. Integral membrane heparan sulfate proteoglycans. FASEB J 7, 1023-1030 (1993). 71. Grassel, S., Cohen, I.R., Murdoch, A.D., Eichstetter, I. & Iozzo, R.V. The proteoglycan perlecan is expressed in the erythroleukemia cell line K562 and is upregulated by sodium butyrate and phorbol ester. Mol Cell Biochem 145, 61-68 (1995). 72. Yoshikawa, T., et al. The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains. Biomaterials 30, 3318-3323 (2009). 73. Silverstein, S.C., Steinman, R.M. & Cohn, Z.A. Endocytosis. Annu Rev Biochem 46, 669-722 (1977). 74. Wolkoff, A.W., Klausner, R.D., Ashwell, G. & Harford, J. Intracellular segregation of asialoglycoproteins and their receptor: a prelysosomal event subsequent to dissociation of the ligand-receptor complex. J Cell Biol 98, 375-381 (1984). 75. Hacker, U., Albrecht, R. & Maniak, M. Fluid-phase uptake by macropinocytosis in Dictyostelium. J Cell Sci 110 ( Pt 2), 105-112 (1997). 76. Ter-Avetisyan, G., et al. Cell entry of arginine-rich peptides is independent of endocytosis. J Biol Chem 284, 3370-3378 (2009). 77. Fretz, M.M., et al. Temperature-, concentration- and cholesterol-dependent translocation of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem J 403, 335-342 (2007). 78. Rothe, R., et al. Characterization of the cell-penetrating properties of the Epstein-Barr virus ZEBRA trans-activator. J Biol Chem 285, 20224-20233 (2010). 79. Lee, J.E. & Lim, H.J. LDP12, a novel cell-permeable peptide derived from L1 capsid protein of the human papillomavirus. Molecular Biology Reports, 1-8. 80. Wu, F.L., et al. RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells. J Biomed Sci 18, 25 (2011). 81. Lee, M.J., et al. Inhibition of LPS-induced nitric oxide production by transduced Tat-arginine deiminase fusion protein in Raw 264.7 cells. BMB Rep 42, 286-292 (2009). 82. Holtsberg, F.W., Ensor, C.M., Steiner, M.R., Bomalaski, J.S. & Clark, M.A. Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties. J Control Release 80, 259-271 (2002). 83. Li, F., et al. Cell-specific induction of apoptosis by microinjection of cytochrome c. Bcl-xL has activity independent of cytochrome c release. J Biol Chem 272, 30299-30305 (1997). 84. Zhivotovsky, B., Orrenius, S., Brustugun, O.T. & Doskeland, S.O. Injected cytochrome c induces apoptosis. Nature 391, 449-450 (1998). 85. Gilmore, K.J., Quinn, H.E. & Wilson, M.R. Pinocytic loading of cytochrome c into intact cells specifically induces caspase-dependent permeabilization of mitochondria: evidence for a cytochrome c feedback loop. Cell Death Differ 8, 631-639 (2001). 86. Alexis, F., Pridgen, E.M., Langer, R. & Farokhzad, O.C. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol, 55-86 (2010). 87. Elbayoumi, T.A., Pabba, S., Roby, A. & Torchilin, V.P. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res 17, 1-14 (2007). 88. Torchilin, V.P. Tatp-mediated intracellular delivery of pharmaceutical nanocarriers. Biochem Soc Trans 35, 816-820 (2007). 89. Morris, M.C., Depollier, J., Mery, J., Heitz, F. & Divita, G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19, 1173-1176 (2001). 90. Garnett, M.C. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev 53, 171-216 (2001). 91. Saito, G., Swanson, J.A. & Lee, K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 55, 199-215 (2003). 92. Fawell, S., et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 91, 664-668 (1994). 93. Zhao, M., Kircher, M.F., Josephson, L. & Weissleder, R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug Chem 13, 840-844 (2002). 94. Liang, J.F. & Yang, V.C. Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 335, 734-738 (2005). 95. Barnes, M.P. & Shen, W.C. Disulfide and thioether linked cytochrome c-oligoarginine conjugates in HeLa cells. Int J Pharm 369, 79-84 (2009). 96. Kerr, D.E., Vrudhula, V.M., Svensson, H.P., Siemers, N.O. & Senter, P.D. Comparison of recombinant and synthetically formed monoclonal antibody-beta-lactamase conjugates for anticancer prodrug activation. Bioconjug Chem 10, 1084-1089 (1999). 97. Qi, L., et al. Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor. Cancer Res 64, 2090-2095 (2004). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/28219 | - |
dc.description.abstract | 肺結核桿菌 (Mycobacterium tuberculosis) 中的肝素結合凝血附著素 (heparin-binding haemaglutinin adhesin , HBHA) C端區域是HBHA蛋白黏合上宿主肺部表皮細胞的重要區段,且主宰了肺結核桿菌的肺外擴散。此C端區域主要由兩個片段重覆排列而成:KKAAPA (R1) 和 KKAAAKK (R2)。過去,實驗室將兩片段依不同排列組合合成出六段胜肽:HBHAa (3R1)、HBHAb (3R1+1R2)、HBHAc (1R1+2R2)、HBHAd (2R1+2R2)、HBHAe (2R2)及HBHA (3R1+2R2),並研究其結合、攝取及穿胞能力的不同。結果顯示,HBHAc在人類肺臟上皮癌細胞 (A549) 與人類結腸癌細胞 (Caco-2) 中,具有極佳的結合、攝取及穿胞能力之最短HBHA相關胜肽;然而,與A549細胞共同培養時,HBHA胜肽的安定性不佳,故為了克服胜肽被降解的問題,本研究將HBHAc胜肽序列上的L-form胺基酸置換成D-form,並比較L- 及D-HBHAc之間的安定性、穿胞能力、細胞內化機制和蛋白質遞送能力。
本研究以人類肺臟上皮癌細胞 (A549) 與人類乳腺癌細胞 (MCF-7) 作為體外研究模式。首先,在適當的蛋白質遞送濃度下,L- 及D-HBHAc並不具有細胞毒性,即使分別投予10-100倍遞送濃度的兩段胜肽,對A549的細胞存活率仍可維持80 – 90%以上;利用逆相高效能液相層析儀分析L- 及D-HBHAc胜肽於細胞培養液中的安定性,發現D-HBHAc在6、16、24小時條件培養液中的安定性,確實優於L-HBHAc,在培養2小時於16小時條件培養液中,L-HBHAc已降解至31.58%,而D-HBHAc仍維持83.55%的完整性。幸運地,D-HBHAc仍保有和L-HBHAc相當的穿胞能力;胜肽濃度對於L- 及D-HBHAc細胞攝取之間的關係,在同種細胞株中,兩段胜肽間並無顯著地不同。 再來,MβCD會顯著地降低L- 及D-HBHAc的細胞攝取,表示兩段胜肽的細胞內化可能與lipid-rafts相關的胞噬作用有關。然而,這兩段胜肽在不同細胞株中的表現並不完全相同。L- 及D-HBHAc胜肽在A549中為部分專一性攝取,但在MCF-7細胞中卻多為非專一性。在A549中,肝素 (heparin) 和硫酸葡聚醣 (dextran sulfate) 確實會降低L- 及D-HBHAc胜肽的細胞攝取,但這個現象在MCF-7細胞中並未觀察到。隨著培養溫度的降低 (攝氏16度及4度),L- 及D-HBHAc胜肽在MCF-7中的細胞攝取亦隨著下降,然而,在A549細胞中,L- 及D-HBHAc胜肽於攝氏16與37度時的細胞攝取,僅有些微差異。 基因重組精胺酸去亞胺酶 (recombinant arginine deiminase,rADI) 雖對大部分肝癌及黑色素癌細胞具有抑制生長之作用,但仍有部分癌細胞對rADI具有抗性,如MCF-7細胞株。為了提高這些抗性癌細胞對rADI的敏感性,故將rADI遞送入細胞中,不僅清除了細胞外的精胺酸也清除了細胞內的。本研究利用rADI作為模式蛋白,研究L- 及D-HBHAc胜肽的蛋白質遞送能力。而細胞內rADI的遞送和細胞存活率分別用流式細胞儀和MTT (二甲基硫醇二苯基四唑溴) 試驗來分析。結果顯示,D-HBHAc-SPDP-rADI比L-HBHAc-SPDP-rADI將更多的rADI運送入MCF-7細胞且顯著地抑制了MCF-7細胞的生長。接著,以超高效能液相層析儀分析細胞內胺基酸的變化,相對於單獨投予rADI,L- 及D-HBHAc接上rADI後,均使得瓜胺酸與精胺酸的比值增加,但這兩種接合體之間並無顯著差異。 總結,本研究指出,在三種不同的條件細胞培養液中,D-HBHAc的安定性優於L-HBHAc。而L- 及D-HBHAc胜肽的細胞攝取專一性與否、與細胞膜之間存在的交互作用及受到溫度的影響,與細胞株的不同有關。利用化學性鍵結胜肽及具有活性的rADI蛋白,可以有效地被運用在蛋白質地遞送,且似乎能夠增加MCF-7對rADI的敏感性。 | zh_TW |
dc.description.abstract | The c-terminal domain of heparin-binding haemaglutinin adhesin (HBHA), a protein from Mycobacterim tuberculosis, has been considered as the crucial domain to adhere to hosts’ pulmonary epithelial cells and mediate extra-pulmonary dissemination. The c-terminal region is identified with two repeated motifs: KKAAPA (R1) and KKAAAKK (R2). In the past, we investigated the characteristics of binding, uptake, and transport in six modified sequences of HBHA-related peptides, including HBHAa (3R1), HBHAb (3R1+1R2), HBHAc (1R1+2R2), HBHAd (2R1+2R2), HBHAe (2R2) and HBHA (3R1+2R2). HBHAc is the shortest peptide of HBHA-related peptides with good ability of binding, uptake and the best ability of transport in A549 and Caco-2 cell models. However, HBHA showed the instability when incubated with A549 cells. In order to overcome the degradation issue, we replaced the L-amino acids with the corresponding D-amino acids of HBHAc. And study the stability, cell-penetrating ability, internalization mechanism, and protein delivery ability between L-HBHAc and D-HBHAc.
Human lung carcinoma epithelial cell line, A549, and human breast adenocarcinoma cell line, MCF-7, were used as in vitro models. First, the stability of L- and D-HBHAc in cell culture supernatant was measured by reverse-phase high performance liquid chromatography (RP-HPLC). We found that L- and D-HBHAc showed non-cytotoxicity at protein delivery concentrations. Even when using 10 -100 fold higher concentrations, L- and D-HBHAc only slightly impaired the cell proliferation in A549. D-HBHAc showed better stability than L-HBHAc in 6, 16, 24 hr-conditional medium. After 2 hr incubation time, the intact L-HBHAc was 31.58% and the intact D-HBHAc still retained 83.55% in 16 hr-conditional medium. Fortunately, D-HBHAc kept the cell-penetrating ability of L-HBHAc. No significant differences were observed on the cellular uptake profiles between these two peptides in A549 or MCF-7. In addition, the cellular uptake of L- and D-HBHAc was significantly decreased with MβCD treatment in A549 and MCF-7 cells. It indicated that L- and D-HBHAc internalize into cells through lipid-rafts dependent endocytosis pathway. However, L- and D-HBHAc had 20% specific uptake of total uptake in A549 cells, but not in MCF-7 cells. Moreover, heparin and dextran sulfate decreased about 50% of the internalization of L- and D-HBHAc in A549. Nevertheless, the phenomenon was not observed in MCF-7 cells. When decreasing the incubation temperature to 16 and 4℃, the cellular uptake of L- and D-HBHAc were significantly reduced in MCF-7. However, the cellular uptake of L- and D-HBHAc only slightly decreased at 16℃ compared to that at 37℃ in A549. Some cancer cells were resistant to recombinant arginine deiminase (rADI), used as an anti-cancer treatment in clinical trials for a range of cancers. To increase the sensitivity of rADI in the resistant cancer cells, intracellular delivery of rADI has been tested by deprivation not only extracellular arginine but also intracellular arginine. We utilized rADI as a protein drug model to investigate the intracellular delivery ability between L- and D-HBHAc. We separately treated L- and D-HBHAc-SPDP-rADI conjugates with rADI-resistant MCF-7. And the intracellular rADI delivery and cell viability were measured by flow cytometry and MTT (3-[4, 5-dimethyl-2-thiazolyl]-2, 5-diphenyl-2H- tetrazolium bromide) assay, respectively. D-HBHAc-SPDP-rADI conjugates significantly increased intracellular rADI delivery and inhibited cell proliferation compared with L-HBHAc-SPDP-rADI conjugates. Subsequently, the intracellular amino acids diversification was performed by UPLC (Ultra Performance Liquid Chromatography). The ratio of intracellular citrulline to arginine under the treatment of L- and D-HBHAc-SPDP-rADI conjugates was significant higher than the one under the treatment of rADI alone. However, there’s no significant difference in citrulline to arginine ratio between these two kinds of conjugates. In conclusion, we demonstrated D-HBHAc showed better stability than L-HBHAc in three different conditional media. The specific uptake, cell membrane interaction, and temperature effects of L- and D-HBHAc were related to cell types. Using chemical linkage to produce peptides and bioactive rADI conjugates is successfully applied in the delivery of proteins and might restore the sensitivity of rADI in MCF-7. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T00:02:58Z (GMT). No. of bitstreams: 1 ntu-100-R98423017-1.pdf: 1852041 bytes, checksum: 7baf3531128057865907da57f4c404a9 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 目錄
目錄 I 圖目錄 V 表目錄 VII 縮寫表 VIII 中文摘要 IX ABSTRACT XI 第1章 緒論 1 1.1 大分子藥物的胞內運輸 1 1.2 細胞穿透胜肽 (cell-penetrating peptides, CPPs) 1 1.3 細胞穿透胜肽的細胞內化過程 (cell internalization and intracellular processing) 2 1.4 肝素結合凝血附著素 (heparin-binding haemagglutinin adhesion, HBHA) 3 1.5 肝素結合凝血附著素胜肽c (heparin-binding haemagglutinin adhesin peptide c, HBHA c) 4 1.6 D-form胺基酸取代策略 (D-amino acids substitution strategies) 5 1.7 精胺酸與基因重組精胺酸去亞胺酶 (arginine and recombinant arginine deiminase, rADI) 6 第2章 實驗目的 8 第3章 實驗材料 10 3.1 細胞培養 10 3.2 L- 及D-HBHAc胜肽合成 10 3.3 高效能液相層析法 10 3.4 胜肽螢光標記 10 3.5 醣類競爭試驗 (Carbohydrates competing assay) 11 3.6 胞噬作用機轉 (Endocytosis inhibitors assay) 11 3.7 溫度對L-及D-HBHAc攝入細胞的影響 11 3.8 細胞存活分析 11 3.9 製備基因重組精胺酸去亞胺酶 (rADI) 11 3.10 蛋白質濃度測定 12 3.11 L- 及D-HBHAc接合rADI 12 3.12 細胞內胺基酸濃度測定 12 第4章 實驗方法 14 4.1 細胞培養 (Cell culture) 14 4.2 細胞存活率試驗 (Cell viability assay) 14 4.3 胜肽安定性試驗 15 4.4 螢光素標記法 (Fluorescein labeling method) 16 4.5 細胞攝取試驗 (Cellular uptake assay) 16 4.6 rADI的運輸 18 4.6.1 rADI的製備 18 4.6.2 rADI的活性測定 (activity assay) 19 4.6.3 rADI的蛋白濃度測定 (BCA assay) 19 4.6.4 rADI之化學性結合物製備 19 4.6.5 以AccQuityTM Ultra performance LCR (UPLC) 進行細胞內胺基酸變化量的分析 (intracellular amino acids diversification) 20 4.7 統計分析 22 第5章 實驗結果 23 5.1 L- 及D-HBHAc具低細胞毒性 23 5.2 L- 及D-HBHAc在細胞培養液中的安定性 24 5.3 L- 及D-HBHAc在A549、MCF-7細胞中的攝取試驗 25 5.4 研究胜肽濃度對L- 及D-HBHAc攝入A549、MCF-7細胞中的影響....... 25 5.5 L- 及D-HBHAc在A549、MCF-7細胞中的攝取專一性/非專一性 (Specific/ nonspecific assay) 26 5.6 L- 及D-HBHAc與A549、MCF-7細胞膜上特殊醣蛋白之間的交互作用 27 5.7 L- 及D-HBHAc進入A549、MCF-7細胞中的胞噬作用機轉 28 5.8 溫度對L- 及D-HBHAc攝入細胞的影響 29 5.9 L- 及D-HBHAc-SPDP-rADI接合體攝入MCF-7細胞的情形 30 5.10 L- 及D-HBHAc-SPDP-rADI接合體的生物活性 30 5.11 L- 及D-HBHAc-SPDP-rADI接合體對於細胞內胺基酸的影響 31 第6章 討論 32 6.1 L- 及D-HBHAc具低細胞毒性 32 6.2 L- 及D-HBHAc在細胞培養液中的安定性 33 6.3 L- 及D-HBHAc在A549、MCF-7細胞中的攝取試驗 34 6.4 研究胜肽濃度對L- 及D-HBHAc攝入A549、MCF-7細胞中影響及其細胞攝取的專一性 34 6.5 L- 及D-HBHAc與A549、MCF-7細胞膜之間的交互作用及內化機制.... 36 6.5.1 細胞膜醣蛋白與L- 及D-HBHAc胞內攝取之間的關係 36 6.5.2 L- 及D-HBHAc的內化途徑 37 6.6 L- 及D-HBHAc-SPDP-rADI接合體在MCF-7細胞的胞內運輸 39 6.6.1 L- 及D-HBHAc-SPDP-rADI接合體對MCF-7細胞存活率的影響... 39 6.6.2 L- 及D-HBHAc-SPDP-rADI接合體對MCF-7細胞內胺基酸的改變 40 6.7 蛋白質藥物之細胞內遞送方式 41 6.8 實驗限制 43 第7章 結論 44 第8章 參考文獻 75 | |
dc.language.iso | zh-TW | |
dc.title | 研究 D-肝素結合凝血附著素c (D-HBHAc) 胜肽之安定性及蛋白質運輸能力 | zh_TW |
dc.title | Investigation on the Stability and Protein delivery of D form Heparin-Binding Haemagglutinin Adhesin c (D-HBHAc) peptide | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃金鼎,林文貞,邱士娟 | |
dc.subject.keyword | 肝素結合凝血附著素,細胞穿透胜肽,d-胺基酸取代,胞噬作用,基因重組精胺酸去亞胺酶,蛋白質遞送, | zh_TW |
dc.subject.keyword | heparin-binding haemaglutinin adhesin,cell-penetrating peptides,d-amino acids replacement,endocytosis,recombinant arginine deiminase,protein delivery, | en |
dc.relation.page | 85 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-08 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.81 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。